23rd week of 2010 patent applcation highlights part 55 |
Patent application number | Title | Published |
20100143228 | ZEOLITE CATALYST FOR REMOVING NITROGEN OXIDES, METHOD FOR PREPARING THE SAME, AND METHOD OF REMOVING NITROGEN OXIDES USING THE SAME - A zeolite catalyst for removing nitrogen oxides is provided, in which 5 to 30 wt % of manganese (Mn) and 2 to 20 wt % of iron (Fe) on the basis of the total weight of the catalyst are supported on zeolite, and a method for preparing the same, and a method for removing nitrogen oxides using the same are provided. | 2010-06-10 |
20100143241 | Method and apparatus for delivery of agents across the blood brain barrier - We describe a method for opening the blood-brain barrier (BBB) using ultrasound and preformed microbubbles. With this method, diagnostic or therapeutic agents may be administered to the brain. This method can open a focal region of the BBB and administer agents in a targeted fashion or the method can open large regions (or the entirety) of the brain for more global administration of agents. In one embodiment, the method can be used to administer contrast agents (e.g., agents that increase or decrease the magnetic resonance imaging signal) to the brain and thereby improve the quality or information content of imaging data. In another embodiment, a standard clinical diagnostic ultrasound scanner can be used to open specific regions of the BBB and administer diagnostic or therapeutic agents. Importantly, this invention can open the BBB in a non-destructive/non-invasive fashion, allowing the subject to be awake and suffer no detectable side effects. | 2010-06-10 |
20100143244 | MONOCLONAL ANTIBODIES TO HUMAN THYMIDINE KINASE TO TREAT CANCER - A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired. | 2010-06-10 |
20100143245 | USES OF MONOCLONAL ANTIBODY 8H9 - The present invention discloses monoclonal antibody 8H9 which binds to the 4Ig domain isoform of the human B7-homolog 3, 4Ig-B7H3. The present invention provides a method of improving the prognosis or prolonging the survival of a subject bearing tumor cells, the method comprises administering to the subject a composition comprising an effective amount of an agent capable of binding to an antigen recognized by monoclonal antibody 8H9. | 2010-06-10 |
20100143246 | Interleukin 17 Receptor-Like Protein - The present invention relates to a novel IL17RLP protein which is a member of the interleukin (IL)-17 receptor family. In particular, isolated nucleic acid molecules are provided encoding the human IL17RLP protein. IL17RLP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of IL17RLP activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating, diagnosing, detecting, and/or preventing immune system-related disorders. | 2010-06-10 |
20100143247 | DIAGNOSIS OF PROSTATE CANCER - The present invention provides a method for determining the presence of prostate cancer in a subject which method comprises determining the level of expression of one or more markers in a blood sample from the subject, wherein said one or more markers comprise at least one of E2F3, c-met, pRB, EZH2, e-cad, CAXII, CAIX, HIF-1α, Jagged, PIM-1, hepsin, RECK, Clusterin, MMP9, MTSP-1, MMP24, MMP15, IGFBP-2, IGFBP-3, E2F4, caveolin, EF-1A, Kallikrein 2, Kallikrein 3 and PSGR. | 2010-06-10 |
20100143250 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS - The present invention relates to a compound of general formula (I) below: Signal−Linker−Peptide (I) in which Signal represents a signal entity; Linker, which may or may not be present, represents a chemical bond and Peptide represents a peptide comprising an apoptosis-targeting peptide, the apoptosis-targeting peptide being chosen from the peptides having the formula below and the functional equivalents thereof:
| 2010-06-10 |
20100143281 | Method for Preparing Personal Care Composition Comprising Surfactant and High Melting Point Fatty Compound - Disclosed is a method of preparing a personal care composition, comprising the steps: (1) preparing a hot oil phase comprising the surfactant and the high melting point fatty compound; (2) preparing a cold aqueous phase comprising the aqueous carrier; and (3) mixing the oil phase and the aqueous phase to form an emulsion; wherein the mixing step (3) comprises the following detailed steps: (3-1) feeding either of the oil phase or the aqueous phase into a high shear field having an energy density of 1.0×10 | 2010-06-10 |
20100143284 | Water-In-Oil Type Emulsion Composition - A water-in-oil type emulsion with a highly moisturizing effect on the skin has good emulsion stability and achieves a good feeling in use as a massage cream when a large amount of perfume is blended. | 2010-06-10 |
20100143288 | HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR ISOFORMS - Disclosed is a novel physiologically active protein, which is a human granulocyte colony stimulating factor isoform, constructed in order to increase the in vivo lifetime of human granulocyte colony sedtimulating factor. The human granulocyte colony stimulating factor isoform comprises a polypeptide and polyethylene glycol (PEG) bound thereto as a non-protein polymer. A specific site of the polypeptide is selected so that polyethylene can be bound to the site while not adversely affecting the activity of the protein. The amino acid of the site is modified with cysteine and polyethylene glycol is bound to the modified site. A pharmaceutical composition comprising the isoforms, genes encoding the isoforms, and a primer for modifying the amino acid sequence are also disclosed. | 2010-06-10 |
20100143290 | MONOCLONAL ANTIBODIES TO HUMAN THYMIDINE KINASE TO TREAT CANCER - A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired. | 2010-06-10 |
20100143291 | Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells - Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity. | 2010-06-10 |
20100143292 | IL-21 VARIANTS - IL-21 variants are provided wherein amino acids have been deleted in the region consisting of amino acid residues no. 65 to 98. | 2010-06-10 |
20100143293 | T cell activation - A method for antigen independent activation of T cells comprising contacting T cells with a combination of cytokines such as two or more of interleukin-2, interleukin-6 and tumor necrosis factor α. | 2010-06-10 |
20100143297 | METHODS OF ENHANCING LYSOSOMAL STORAGE DISEASE THERAPY BY MODULATION OF CELL SURFACE RECEPTOR DENSITY - Methods of modulating uptake of extracellular lysosomal enzymes by administering a pharmaceutical agent and methods of treating a lysosomal storage disease (such as Gaucher disease, Pompe disease, Fabry disease or Niemann-Pick disease) or enhancing enzyme replacement therapy or gene therapy, comprising administering a pharmaceutical agent such as dexamethasone, glucose or insulin, are provided. | 2010-06-10 |
20100143298 | COLLOIDAL METAL COMPOSITIONS AND METHODS - The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer. | 2010-06-10 |
20100143300 | HEPATITIS C THERAPIES - The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections. | 2010-06-10 |
20100143303 | COMPOSITION COMPRISING LACTIC ACID BACTERIUM HAVING HIGH ANTI-ALLERGIC ACTIVITY, AND METHOD FOR PRODUCTION OF THE LACTIC ACID BACTERIUM - It is to provide a lactic acid bacterium having a high antiallergic activity and stable antiallergic activity that can be used effectively in various product forms and in various use applications. By conducting a heat treatment at 60 C. or more and less than 100° C. for 10 minutes or more and less than 60 minutes to | 2010-06-10 |
20100143306 | USE OF BONE MARROW CELLS FOR LONG TERM CULTURE OF PANCREATIC ISLET CELLS - Bone marrow cells have been demonstrated to be useful in the maintenance of pancreatic islet β cell viability, structure, and/or function in culture for a sustained period. Bone marrow cells were also found to promote β cell growth while reducing inflammatory cytokine release and reduce apoptosis. Moreover, islet cells co-cultured with bone marrow cells were shown to retain insulin response function and to function in an islet cell transplant in a mouse model of diabetes to restore normal insulin secretion. Cord blood cells and isolated peripheral CD34+ blood cells were unable to support β islet cell growth or increase survival. | 2010-06-10 |
20100143307 | Use of Penicillin G Procaine as a selective antimicrobial agent in the production of alcohol by fermentation - A process for the use of low concentration levels of Penicillin G Procaine to eliminate or control the growth of unwanted or undesirable bacteria (contaminating bacteria) in the fermentation production of alcohol without inhibition of the growth or replication of the yeast. | 2010-06-10 |
20100143308 | AKT NUCLEIC ACIDS, POLYPEPTIDES, AND USES THEREOF - The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis. | 2010-06-10 |
20100143321 | THERAPEUTIC COMPOSITION FOR INTERSTITUAL PNEUMONIA - A therapeutic agent for interstitial pneumonia is provided which effectively exploits the effect of superoxide dismutase (SOD). The therapeutic composition for interstitial pneumonia contains 10 to 100 mg of lecithinized superoxide dismutase represented by the following general formula (I): | 2010-06-10 |
20100143322 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE - The present invention relates to the use of inhibitors of different N-methyl transferases in the therapy of Parkinson's syndrome, in particular idiopathic Parkinson's syndrome. | 2010-06-10 |
20100143324 | METHOD FOR TREATMENT OF CANCERS OR INFLAMMATORY DISEASES - The invention concerns a glycosylasparaginase polypeptide with L-asparaginase activity or its precursor for use in the treatment or prevention of cancers or inflammatory diseases. The invention concerns also a novel pharmaceutical composition comprising either i) the glycosylasparaginase polypeptide or its precursor, or ii) an expression vector encompassing a nucleic acid sequence encoding the glycosylasparaginase polypeptide or its precursor for use in the treatment or prevention of cancers or inflammatory diseases. | 2010-06-10 |
20100143325 | Composition And Methods Involving Thrombolytic Agents - Treatment or prevention methods are described wherein t-PA and C1-inhibtor are used together in order to minimize the hemorrhagic complications of tPA Preferably, C1-inhibitor is infused prior to treatment with t-PA, thereby allowing for a safer thrombolysis without the excessive and dangerous bleeding associated with the use of t-PA alone particularly in the treatment of ischemic stroke. | 2010-06-10 |
20100143330 | METHODS OF TREATING DISORDERS ASSOCIATED WITH FAT STORAGE - The invention relates, in general, to markers of obesity and lipodystrophy. In particular, the expression level of the SLUG gene or its expression products can be used as such a marker. Furthermore, the invention additionally relates to the use of SLUG as a therapeutic and diagnostic target for these pathologies. The invention further relates to a method of treating a disorder associated with increased or decreased fat storage in a mammal comprising modulating the activity or level of the SLUG protein or the SLUG gene in the mammal. | 2010-06-10 |
20100143332 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS - The present invention provides compositions and methods of treating proliferative disorders using combination therapy with a first agent that specifically inhibits DNA polymerase alpha and a second agent that inhibits protein kinases, such as Chk1. | 2010-06-10 |
20100143333 | METHOD OF TREATING DIABETES - The present invention relates to a method for treating a subject having or at risk of a diabetes-related disorder. In a preferred embodiment, the method involves increasing the level or activity of Hypoxia Induced Factor 1 (HIF-1 α) in pancreatic-β-cells or insulin-sensitive tissues in the subject by administering to the subject an inhibitor of a protein that decreases the level or activity of HIF-1α. The present invention also relates to a method of transplanting pancreatic islet cells in a subject. | 2010-06-10 |
20100143335 | TREATING ATHEROSCLEROSIS - The present application features methods and compositions for treating patients suffering from atherosclerosis or at risk for developing atherosclerosis. The treatment includes administering to the patient a pharmaceutical composition that includes an agent capable of blocking the interaction between uPA and its receptor uPAR, e.g., an ATF or a fragment thereof, an anti-uPA antibody, a uPAR or a fragment thereof, or an antibody that specifically binds to uPAR. | 2010-06-10 |
20100143336 | TOLL-LIKE RECEPTOR BINDING EPITOPE AND COMPOSITIONS FOR BINDING THERETO - The present invention relates to the identification of an epitope defined by residues of Toll-like Receptor (2). Targeting a binding compound, such as an antibody to the epitope results in antagonism of Toll-like Receptor (2). Further provided by the invention is the use of polypeptide comprising amino acid residues which form the epitope for use in screening for binding compounds which bind thereto, as well as to polypeptide compound which comprise the amino acid sequences of the epitope for use as vaccine compositions, when the generation of antagonistic antibodies which have binding specificity to Toll-like Receptor (2) are required, for example in the treatment of Toll-like Receptor (2) mediated disease conditions. | 2010-06-10 |
20100143339 | METHODS OF TREATING AND PREVENTING COLITIS INVOLVING IL-13 AND NK-T CELLS - Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. | 2010-06-10 |
20100143361 | METHODS FOR THE TREATMENT OF A-BETA RELATED DISORDERS AND COMPOSITIONS THEREFOR - The invention provides methods for treating Aβ peptide related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 modulator to a patient in need thereof. | 2010-06-10 |
20100143364 | Chimeric Antibodies, Compositions and Methods for Treating Cocaine-Related Disorders - The invention relates to antibodies, including chimeric monoclonal antibodies, and fragments thereof, that bind to cocaine. The invention also relates to the use of these or any anti-cocaine antibodies, derivatives or variants in the prevention or treatment of cocaine-related disorders and in the amelioration of one or more symptoms associated with a cocaine-related disorder. | 2010-06-10 |
20100143367 | NOVEL ANTI-CD98 ANTIBODY - A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided. | 2010-06-10 |
20100143368 | Human Antibodies That Bind Cd22 And Uses Thereof - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure. | 2010-06-10 |
20100143369 | Interferon Alpha Receptor I Antibodies And Their Use - The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention. | 2010-06-10 |
20100143371 | INTRABODIES - A single domain intrabody that binds to an intracellular protein or to an intracellular domain of an intracellular protein, such as Etk. Also provided is a method of inhibiting an intracellular enzyme, and treating a tumor in a patient by administering the intrabody or a nucleic acid expressing the inventive intrabody. | 2010-06-10 |
20100143372 | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS - The present invention encompasses type-1 IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders. | 2010-06-10 |
20100143374 | DIAGNOSTIC AND THERAPEUTIC TARGET FOR AUTOIMMUNE DISEASES AND USES THEREOF - Described is the identification of ZnT8 as an autoantigen target in type I autoimmune diabetes (T1D), other autoimmune disease, and other diabetes-linked diseases and conditions. Also described are a variety of therapeutic, diagnostic, and prognostic tools and methods based on this discovery. The identification of genetic variation in ZnT8 as an important player in the initiation of the disease process and the progression of autoimmunity to clinical diabetes is disclosed. | 2010-06-10 |
20100143376 | Antibodies Specific for Rubella Virus - The present invention provides novel antibody sequences that bind and neutralize Rubella Virus (RuV). The novel sequences can be used for the medical management of RuV infection, in particular for detecting the virus or for preparing pharmaceutical compositions. The RuV-specific antigens recognized by such antibody sequences can be identified using novel phage libraries that display peptides. | 2010-06-10 |
20100143379 | MIF AGONISTS AND ANTAGONIST AND THERAPEUTIC USES THEREOF - The present invention relates to methods and compositions for selecting a subject for treatment with an agonist or antagonist of macrophage migration inhibitory factor (MIF), identifying a subject at risk for developing a disease associated with high or low MIF expression, predicting the severity of a disease associated with high or low MIF expression in a subject, and for predicting whether a subject is susceptible to a disease associated with high or low MIF expression. The invention also provides novel methods of diagnosing a patient for a disease associated with high or low MIF expression. Also provided are methods for treating a subject having a disease or disorder associated with high or low MIF expression. | 2010-06-10 |
20100143411 | METHOD FOR IDENTIFICATION OF T-LYMPHOCYTE ANTIGENS - A method for high-throughput identification of antigens is disclosed. The method involves generating transcriptionally active PCR (TAP) products of one or more antigen candidates and expressing the TAP products in an in vitro translation transcription (IVTT) system. The TAP products are purified using identifiable tags. The purified TAP products are presented to isolated antigen-presenting cells (APCs), which are in turn are presented to T-cells. The ability of the antigen candidates to induce activation of the T-cells is determined. Activation of the T-cells identifies the antigen candidate as an antigen. Immunogenic compositions and methods of treatment using such compositions are also disclosed. | 2010-06-10 |
20100143414 | PNEUMOCOCCAL SEROTYPES - Disclosed is a new and emerging serotype of | 2010-06-10 |
20100143415 | Streptococcus Pneumoniae Antigens - There are provided various novel antigens from | 2010-06-10 |
20100143416 | Alpha-defensins as anthrax immunotherapeutis - The present invention relates to the use of an alpha-defensin in the manufacture of a medicament for the treatment, amelioration or prevention of a disease caused by | 2010-06-10 |
20100143418 | Immunising Against Meningococcal Serogroup Y Using Proteins - The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W | 2010-06-10 |
20100143420 | MULTI-PHASIC PHARMACEUTICAL FORMULATIONS OF POORLY WATER-SOLUBLE DRUGS FOR REDUCED FED/FASTED VARIABILITY AND IMPROVED ORAL BIOAVAILABILITY - Pharmaceutical formulations are disclosed comprising a multi-phasic pharmaceutical composition comprising an active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is in a particulate state, a solubilized state, or in both a particulate state and in a solubilized state; a solvent; a non-miscible liquid; a stabilizer, and water; wherein the pharmaceutical formulation is an oral dosage form. Such pharmaceutical formulations are capable of reducing the fed/fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and improved oral bioavailability. | 2010-06-10 |
20100143431 | BIOACTIVE, RUTHENIUM-CONTAINING COATING AND DEVICE - The invention relates to the production and use of novel bioactive devices and metallic coatings for example for sterilizing, disinfecting, and decontaminating water or aqueous solutions. The known oligodynamic effect of silver for reducing the amount of germs is thereby improved and increased by combining silver with ruthenium and a vitamin or derivative thereof. The novel properties of these bioactive metal surfaces lead to faster and more efficient killing of microorganisms. Simultaneously, these novel bioactive metal surfaces prevent infestation by microorganisms and attachment or permanent deposition of problematic biomolecules such as for example DNA, RNA, or proteins. A self-cleaning surface is thus obtained, which very quickly and efficiently and over extended periods of time sterilizes water and aqueous solutions when they come in contact with said surface. | 2010-06-10 |
20100143435 | SCAFFOLD WITH INCREASED PORE SIZE - The invention relates to scaffolds for use as medical devices, for guided tissue regeneration and repair, wherein the relationship between fibre diameter and pore size in a scaffold is decoupled, thereby enabling the small fibre diameters required for cell attachment and proliferation and the large pore sizes needed for cell migration into the scaffold to be achieved. | 2010-06-10 |
20100143437 | IMPLANTABLE ANALGESIC - A method and device for implantable analgesics having a plurality of analgesia containing portions that are capable of being sequentially released. | 2010-06-10 |
20100143438 | BIOMOLECULES - A substrate is provided having a biomolecule immobilised thereon, wherein the biomolecule is connected via an enzyme-cleavable link to a blocking moiety such that cleavage of the link causes removal of the blocking moiety and activation of the biomolecule. | 2010-06-10 |
20100143441 | NORTRIPTYLINE COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 2010-06-10 |
20100143442 | GROWTH FACTOR COMPLEXES AND MODULATION OF CELL MIGRATION AND GROWTH - Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer. | 2010-06-10 |
20100143446 | Novel skin moisturizing compositions - Novel skin moisturizing compositions are applied onto dry skin, particularly mild to moderately dry skin, are non-irritating and contain at least one natural moisturizing factor, | 2010-06-10 |
20100143450 | DEVELOPMENT OF ASTHMA THERAPY WITH rAAV-mediated AMCase shRNA - The invention provides small interfering RNA (siRNA) and their carriers that could treat asthma in mammalian through inhibiting acidic mammalian chitinase (AMCase) gene expression. The invention further provides a composition comprising siRNA of the present invention and a carrier. The invention also provides a method for treating asthma of a subject. | 2010-06-10 |
20100143492 | COAGULATION AND FIBRINOLYTIC CASCADES MODULATOR - A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker. | 2010-06-10 |
20100143493 | OPHTHALMIC SOLUTIONS - An ophthalmic solution comprising a hydrogen peroxide source in an amount sufficient to result in between about 0.001% and about 0.01% by weight stabilized hydrogen peroxide in said formulation as a preservative, one or more ocularly-compatible hydrogen peroxide stabilizers, hydroxypropylmethylcellulose and sodium carboxymethylcellulose, as well as pharmaceutical compositions comprising such solutions, are provided. | 2010-06-10 |
20100143494 | Natural Silver Disinfectant Compositions - An antimicrobial composition contains a soluble silver salt and an alkanolamine or aminoalcohol. The composition may additionally contain an amino acid or amino acid salt and surfactant. The composition has additional stability and activity compared to prior art silver complexes. | 2010-06-10 |
20100143496 | TWO-PART DISINFECTANT SYSTEM AND RELATED METHODS - The present disclosure is drawn to a disinfectant system which can be used to disinfect surfaces. The system includes a first chamber containing a first solution and a second chamber containing a second solution. The first solution can include an alcohol, an organic carboxylic acid, and from 0.01 ppm, to 1,000 ppm by weight of a transition metal or alloy thereof based on the first solution weight content. The second solution can include hydrogen peroxide. The system further includes a dispenser through which the system is configured to mix and dispense the first solution and the second solution immediately before being dispensed. A peracid composition is formed upon mixing of the first and second solutions. | 2010-06-10 |
20100143498 | INFUSION SOLUTION FOR PERIPHERAL INTRAVENOUS ADMINISTRATION - There is provided an infusion solution for peripheral intravenous administration comprising a multichamber vessel constructed in a connectable manner, which separately houses a sugar solution containing sugars, electrolytes and vitamin B1, and an amino acid solution containing amino acids, electrolytes and a sulfite, whereby the vitamin B1 and amino acids are stably maintained. In the infusion solution for peripheral intravenous administration, the sugar solution contains calcium gluconate, contains no greater than 1.4 g/L sodium lactate, has a pH of 4.0-4.7 and has a titratable acidity of 2-4, the amino acid solution contains 4.0-8.0 g/L sodium lactate, contains no calcium gluconate, has a pH of 6.8-7.2, contains free L-cysteine as cysteine and contains 0.05-0.2 g/L sodium hydrogen sulfite, and after the sugar solution and amino acid solution have been mixed, the infusion solution has a pH of 6.5-7.1 and a titratable acidity of 5-10. | 2010-06-10 |
20100143500 | Methods and Compositions for Inhibiting GSK-3 In Glial Cell Related Disorders - A method of treating a glial cell related disorder in a mammalian subject includes administering a drug which enhances or prolongs GSK-3 α or β inactivation. | 2010-06-10 |
20100143502 | PLANT WASH - A plant wash comprising a mixture of dormant oil and hop extract in a carrier is useful for protecting fruit trees against freeze damage, bacterium, pest infestations, fungi and wilt. | 2010-06-10 |
20100143503 | COMBINATIONS OF NITRIC OXIDE AND SULFIDE AND METHODS OF USE AND MANUFACTURE THEREOF - The present invention provides methods of reducing the cytotoxic effects of nitric oxide and sulfides comprising coadministering nitric oxide with sulfide. In addition, the present invention provides novel pharmaceutical compositions comprising both nitric oxide and sulfide. The methods and compositions of the present invention may be used in the treatment or prevention of a variety of diseases and disorders, and also in the prevention of cell or tissue damage, including that resulting from ischemi hypoxia. | 2010-06-10 |
20100143505 | INDANONE INHIBITORS OF ACETYLCHOLINESTERASE - The present invention relates to new indanone inhibitors of acetylcholinesterase, pharmaceutical compositions thereof, and methods of use thereof. | 2010-06-10 |
20100143507 | CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMINASE AND SODIUM CHANNEL - The present invention relates to new carboxylic acid inhibitors of histone deacetylase, GABA transaminase, and/or sodium channel activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-06-10 |
20100143509 | THERAPEUTIC COMPOSITIONS FROM JAMAICAN BITTER YAM AND METHODS OF MAKING AND USING SAME - The invention relates to therapeutic compositions, in particular to therapeutic compositions made from Jamaican bitter yam that are substantially free of tannins and alkaloids and comprise fiber, and methods of making and using such therapeutic compositions. | 2010-06-10 |
20100143511 | SCUTELLARIA BARBATA EXTRACT FOR THE TREATMENT OF CANCER - An extract of | 2010-06-10 |
20100143512 | NOVEL SEBUM SECRETION INHIBITORY AGENT - The present invention relates to a novel sebum secretion inhibitor and use thereof for the production of cosmetic and pharmaceutical, notably dermatological, compositions, intended for preventing and/or reducing the secretion of sebum and notably of squalene. | 2010-06-10 |
20100143514 | ANTIVIRAL AGENTS CONTAINING A FERMENTATION PRODUCT OF GARLIC BY LACTIC ACID BACTERIA - An antiviral substance including a fermentation product of garlic that is fermented by lactic acid bacteria is provided. More specifically, an antiviral agent including a fermentation product of garlic, that is fermented by lactic acid bacteria, as an active ingredient is provided. The antiviral agent including a fermentation product of garlic fermented by lactic acid bacteria is useful as a preventing or treating agent of viral infection by inhibiting viruses. | 2010-06-10 |
20100143519 | MACHINE FOR ROTATIONAL MOLDING WITH HEATED MOLD AND WITH FACILITATED PART EXTRACTION - A machine for rotational molding of products comprises means ( | 2010-06-10 |
20100143520 | EXTRUDER SYSTEM AND CUTTING ASSEMBLY - An extruder system for extruding material through a die/extrude insert in an opening in an extruder plate. | 2010-06-10 |
20100143541 | FERMENTED FOOD OR DRINK PROCDUCT, AND METHOD FOR PRODUCING THE SAME - The present invention relates to a method for producing a fermented food or drink product, including: adding a strain of lactic acid bacteria which belongs to | 2010-06-10 |
20100143542 | CREAM SUBSTITUTE - The present invention describes a food product comprising from 0.1 to 2.5 wt % of a starch which is treated with an amylomaltase. | 2010-06-10 |
20100143547 | Pet Container And Compositions Having Enhanced Mechanical Properties And Gas Barrier Properties - A container comprising a polyester composition with enhanced mechanical properties is provided. The polyester composition comprises a polyester and a creep control agent. In particular embodiments, the polyester composition comprises a polyester, a creep control agent, and a gas barrier additive. In particular embodiments, the creep control agents are molecules or polymers comprising dianhydrides, bis-lactams, bis-oxazoles, and epoxides. | 2010-06-10 |
20100143548 | GUM SLAB PACKAGE HAVING INSERTABLE PRODUCT RETENTION MEMBER - A package assembly encloses a plurality of individual elongate consumable products. The package assembly includes a plurality of products aligned in a side-by-side array. The package housing enclosed the array of product. The package housing has front and back walls for supporting the products therebetween and a closeable cover for closing a product dispensing opening. The package housing further includes a frictional product retention member insertably supported within the package for frictionally retaining the array of product within the package. | 2010-06-10 |
20100143549 | Apparatus, pods and methods for processing expandable food materials - The present invention relates in general to methods and apparatus for processing expandable food materials, and more particularly to methods and apparatus for low shear thermo-mechanical processing of food materials and unique pods for use in connection with such methods and apparatus. The invention can include cooker and extruder apparatus for the customized production of food products, including a compression module, a dryer module, and a control unit, that interact with the pods to produce desired food product. | 2010-06-10 |
20100143550 | SAVOURY FOOD PRODUCT AND PROCESS TO PREPARE THE SAME - Savoury food product, comprising salt and/or fat, and further comprising a plant material comprising chlorophyll, and a food grade blue-coloured ingredient. | 2010-06-10 |
20100143565 | Chilled Ingredient for Beverages - A method of preparing a pre-blended beverage ingredient for use in the preparation of chilled beverages includes the steps of placing ice cubes or other pieces of solid ice together with a volume of liquid in a blending apparatus having vessel for receiving product to be blended and an impeller or other mixing or blending means arranged for high speed blending of product within the vessel, and then blending the ice within the liquid to produce a mixture of chilled liquid and a soft paste-like substance. The ice is substantially immersed in said volume of liquid prior to blending and any excess liquid is strained from the paste after blending. | 2010-06-10 |
20100143566 | Frozen Aerated Confections and Methods for Producing Them - A frozen aerated confection is provided, the confection comprising at least 0.2 wt % free β-casein, wherein the free β-casein constitutes more than 45% of the total β-casein present in the frozen confection; and containing a population of gas bubbles, wherein at least 65% of the gas bubbles have a diameter of less than 20 μm. A process for producing such a frozen aerated confection is also provided. | 2010-06-10 |
20100143567 | DAIRY PRODUCT AND PROCESS - A viscoelastic fluid is prepared by shearing a gelled emulsion. The emulsion is an oil-in-water emulsion comprising 2% 12% (w/w) of a heat-treated protein that can form a heat-set gel and 5% 40% fat. The proteins used include whey protein and soy protein. The viscoelastic fluid may be used as a spread. It may also be used for the preparation of a plurality of different ultimate products formed from the original gel. | 2010-06-10 |
20100143570 | Omega-9 quality brassica juncea - The invention relates to improved | 2010-06-10 |
20100143581 | Micro-Extrusion Printhead With Nozzle Valves - A solar cell extrusion printing system includes a printhead assembly having one or more elongated valve structures that are adjustably disposed adjacent to the outlet orifices of selected nozzle channels, and a valve control device for controlling the position of the valve structures to facilitate controllable ink flow through selected nozzle channels of the printhead assembly during the gridline printing process. The printhead assembly defines an elongated opening (e.g., a slot or hole) that that intersects (i.e., passes through) each of the selected nozzle channels, and an elongated member is movably disposed in the slot and is selectively movable between a first (opened) position, in which the valve structure extrusion material is passed by the valve structure through the nozzle channel and out of the printhead, and a closed position, in which the extrusion material is blocked by the valve structure and prevented from passing through the nozzle channel. | 2010-06-10 |
20100143583 | ENERGY DEVICE AND METHOD FOR PRODUCING THE SAME - A negative active material thin film containing silicon as a main component is formed on a collector. A composition gradient layer, in which a composition distribution of a main component element of the collector and silicon is varied smoothly, is formed in the vicinity of the interface between the collector and the negative active material thin film. The composition gradient layer contains at least one kind of third element selected from W, Mo, Cr, Co, Fe, Mn, Ni, and P, in addition to the elements contained in the collector and the elements contained in the negative active material thin film. The third element irregularizes the atomic arrangement at the interface between the collector and the negative active material thin film. Therefore, even when the negative active material absorbs/desorbs ions during charging/discharging, thereby allowing silicon particles in the negative active material to expand/contract, the strain at the interface involved in the expansion/contraction of the silicon particles is alleviated, and peeling at the interface between the negative active material thin film and the collector is suppressed. Consequently, cycle characteristics are enhanced. | 2010-06-10 |
20100143585 | CARBON BLACK PELLETS AND METHOD OF FORMING SAME - A carbon black pellet comprising an inner core of de-aerated carbon black and an outer surrounding shell of an encapsulating material, the shell of the encapsulating material having an average thickness of from about 1% to about 10% of the average thickness of the pellet. | 2010-06-10 |
20100143586 | Spin coating apparatus, spin coating method, and method for manufacturing information recording medium - The spin coating apparatus includes: a collet including a tubular portion disposed coaxially with a predetermined rotation axis, the tubular portion having a slit that extends from a top portion of the tubular portion in a direction of the rotation axis to a midway part in the direction of the rotation axis; and a diameter-expanding member for urging the tubular portion of the collet radially outwardly to expand the outer diameter of the tubular portion. With the spin coating apparatus, a plate-like workpiece having a center hole is held at the center hole by the tubular portion of the collet with both sides of the workpiece exposed, and a flowable material can be applied to both the sides of the workpiece. | 2010-06-10 |
20100143587 | VAPOR DEPOSITION APPARATUS AND VAPOR DEPOSITION METHOD - A vapor deposition apparatus includes a linear head including a plurality of nozzles, and an angle controller controlling an inclined angle of the linear head. The angle of inclination of the linear head can be varied so as to position different portions of the linear head at different distances from the surface of a substrate. | 2010-06-10 |
20100143588 | CHEMICAL VAPOR DEPOSITION FLOW INLET ELEMENTS AND METHODS - A flow inlet element ( | 2010-06-10 |
20100143613 | Cellulose Acylate Film, Polarizing Plate and Liquid Crystal Display - A cellulose acylate film satisfying the following formulae: | 2010-06-10 |
20100143614 | Holiday and event bubble wrap - The bubble wrap of the present invention includes glitter or confetti, or both encapsulated into the bubbles of the bubble wrap and embedded between the layers of film. One or both layers of plastic which comprise the bubble wrap can be colored, or printed to accentuate the holiday or event being celebrated. A method for making the bubble wrap is also provided. | 2010-06-10 |
20100143616 | HEAT-SENSITIVE TRANSFER IMAGE-RECEIVING SHEET AND METHOD OF PRODUCING THE SAME - A heat-sensitive transfer image-receiving sheet having a receptor layer comprising: (a) a polymer or latex polymer including a unit having ultraviolet absorbing ability, or (b) a latex polymer and a water-soluble polymer; and a method of producing the same. | 2010-06-10 |
20100143617 | CORE STRUCTURE AND METHOD FOR PRODUCING A CORE STRUCTURE - The present invention relates to a method for producing a core structure. Firstly, a first core structure and a second core structure are fastened. The first core structure and the second core structure are positioned at a defined distance. A reinforcement element is introduced into a cavity between the first core structure layer and the second core structure layer. The reinforcement element, the first core structure layer, and the second core structure layer form a self-supporting core structure. | 2010-06-10 |
20100143619 | Thermal Conduction Principle And Device For Intercrossed Structure Having Different Thermal Characteristics - The present invention relates to relay thermal conductor made of material having better thermal conductivity coefficient, wherein which is thermal conductively coupled with heating or cooling first thermal body at one end or face thereof, and is coupled with interface thermal conductor having higher specific heat capacity at the other end or face thereof; the relay thermal conductor directly performs thermal conduction with second thermal body at another part thereof; and the interface thermal conductor having higher specific heat capacity is the thermal conducting carrier between the relay thermal conductor and the second thermal body. | 2010-06-10 |
20100143651 | FUNCTIONALIZED OLEFIN POLYMERS, COMPOSITIONS AND ARTICLES PREPARED THEREFROM, AND METHODS FOR MAKING THE SAME - The invention provides polyolefin blend compositions of polar and/or non-polar polymers, with at least one functionalized polyolefin polymer selected from the group consisting of: amine functionalized, hydroxyl functionalized, imide functionalized, anhydride functionalized, or carboxylic acid functionalized polyolefin polymers. The invention also provides methods for making the functionalized polyolefin polymer. The invention also provides for materials and articles containing at least one component prepared from such compositions. | 2010-06-10 |
20100143652 | COMPOSITE - A composite structure including a substrate and a fluid in contact with the substrate, wherein the substrate comprises a non-woven, a foam, or combinations thereof and is characterized by having a basis weight of 15 to 500 grams per square meter. | 2010-06-10 |
20100143656 | Method and Structure for Adapting Solder Column to Warped Substrate - A multiple substrate system, a method, and structure for adapting solder volume to a warped module. An illustrative embodiment comprises a method for joining a first substrate to a second substrate. A deviation from a nominal gap between the first substrate and the second substrate at a first region of the first substrate is ascertained. A volume of solder paste necessary to compensate for the deviation from a nominal gap is determined. The volume of solder paste necessary to compensate for the deviation at the first region of the first substrate is applied. Further, the second substrate is bonded to the first substrate using, at least in part, the solder paste applied at the first region of the first substrate. | 2010-06-10 |
20100143657 | HIGH-TEMPERATURE-DURABLE OPTICAL FILM STRUCTURE AND FABRICATION METHOD THEREOF - A high-temperature-durable optical film structure and its fabricating method are provided. The optical film structure is formed by covering a surface of a substrate with an optical layer structure and forming a plurality of passage structures on the optical layer structure to divide the optical layer structure into a plurality of optical blocks. The passage structures can be used as a space of releasing the thermal stress to prevent the film deformation and peeling. | 2010-06-10 |
20100143662 | ARCHITECTURAL RESIN PANELS WITH TRANSLUCENT VENEER LAYERS - Implementations of the present invention relate aesthetically pleasing decorative architectural resin panels having a thin or brittle veneer layer, such as thinly sliced natural wood or stone. In particular, at least one implementation includes a flat or curved decorative resin panel made with a natural wood veneer layer whose structural integrity has been maintained despite being subject to various heats and pressures. The resulting resin panel is at least partially translucent, and allows for a unique display both of the resin sheets used to form the panel and of the thin wood materials encapsulated therein. Additional implementations relate to the use of other brittle veneer layers, such as translucent stone, translucent metals, or the like, which also provide unique, decorative architectural, aesthetic features. | 2010-06-10 |
20100143665 | PATTERNED FINE PARTICLE FILM STRUCTURES - A patterned fine particle film structure includes a fine particle layer including fine particles arranged and bound to a surface of a substrate coated with a patterned film including a first film compound having a first functional group. The fine particles are coated with films including a first coupling agent having a first coupling reactive group that undergoes a coupling reaction with the first functional group to form a bond. The fine particle layer is bound by a bond formed through a coupling reaction. In an embodiment, fine particles coated with films of a film compound that reacts with the first coupling reactive group and the fine particles are alternately bound to the substrate. | 2010-06-10 |
20100143666 | REDOX ACTIVATED PATTERNING - A method of forming a target pattern using a redox activated surface is disclosed. The method includes patterning a redox agent on a template layer formed on a substrate, the template layer having a first oxidation state, wherein upon contact with the redox agent, the contacted portion of the template layer changes to a second oxidation state different than the first oxidation state, and a template pattern is formed from the portion of the template layer having either the first oxidation state or the second oxidation state, and exposing the substrate having the template pattern to a target material, wherein the target material selectively binds to the template pattern to form a target pattern. | 2010-06-10 |
20100143667 | Print Methodology for Applying Polymer Materials To Roofing Materials to Form Nail Tabs or Reinforcing Strips - A method and apparatus for applying nail tabs to roofing and building cover materials involving the steps of depositing tab material onto the surface of the roofing or building cover material, during or after its manufacture, resulting in a plurality of nail tabs from a lamination roll, and bonding the tabs to the surface of the material by pressure between the lamination roll and said surface. The method also encompasses depositing the tab material or pre-formed tabs by a pressure roll in contact with said surface. The tabs preferably are made substantially of a polymer material and may be hardened or cured by ultra-violet or visible light. The tabs may also be pre-formed and have adhesive backing. | 2010-06-10 |